Diabetes Mellitus Type 2 — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for diabetes mellitus type 2. 1122 active patents protecting 11 drugs from 8+ originators. First major cliff: 2037. Daily refresh.

11
Approved drugs
1122
Active US patents
58/100
Avg vulnerability
$63.7B
Annual revenue covered

Originators in Diabetes Mellitus Type 2

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Boehringer Ingelheim 479 patents Eli Lilly 216 patents Novo Nordisk 182 patents AstraZeneca 144 patents Johnson & Johnson 64 patents Merck & Co. 24 patents Theracosbio 6 patents Sanofi 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating diabetes mellitus type 2. Each bar = one year. Y-axis scaled to peak year (227 patents).

26
26
125
27
74
28
96
29
142
30
59
31
20
32
37
33
227
34
3
35
48
36
37
37
23
38
160
39
11
40
8
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Jardiance
empagliflozin
 Boehringer Ingelheim 388 64 $6.5B 2027-04-15
Mounjaro
TIRZEPATIDE
 Eli Lilly 216 62 $15.5B 2036-01-05
Ozempic
semaglutide
 Novo Nordisk 178 44 $27.4B 2026-07-17
Farxiga
DAPAGLIFLOZIN
 AstraZeneca 144 64 $6.3B 2026-08-18
Tradjenta
LINAGLIPTIN
 Boehringer Ingelheim 91 51 $800M 2027-05-04
Invokana
CANAGLIFLOZIN
 Johnson & Johnson 64 65 $800M 2027-07-14
Steglatro
ERTUGLIFLOZIN
 Merck & Co. 24 65 — 2026-11-24
Brenzavvy
BEXAGLIFLOZIN
 Theracosbio 6 60 — 2028-08-22
Victoza
liraglutide
 Novo Nordisk 4 54 $3.2B 2037-01-09
Amaryl
GLIMEPIRIDE
 Sanofi 4 63 — 2027-01-30
Januvia
SITAGLIPTIN
 Zydus Lifesciences 3 50 $3.2B 2035-02-25

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8106021 Brenzavvy method of use 83 2028-08-22
8802637 Brenzavvy method of use 83 2028-08-22
7838499 Brenzavvy method of use 83 2029-01-30
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8129343 Ozempic composition of matter 0 2031-12-05
8129343 Ozempic composition of matter 0 2031-12-05
8129343 Ozempic composition of matter 0 2031-12-05
8129343 Ozempic composition of matter 0 2031-12-05
8129343 Ozempic composition of matter 0 2031-12-05
11382957 Ozempic composition of matter 6 2031-12-16
11382957 Ozempic composition of matter 6 2031-12-16
11382957 Ozempic composition of matter 6 2031-12-16
8129343 Ozempic composition of matter 6 2031-12-05
8129343 Ozempic composition of matter 6 2031-12-05

Related